USTR report criticises pharma policies in Japan, NZ, Turkey
28-04-2022
India removes cap from patented rare disease drugs
07-01-2019
fabioberti / Shutterstock.com
The lobby group for India’s pharma industry has asked the US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Trade Representative, Indian Pharmaceutical Alliance, Indian Patent Office, priority watch list, patents, trademarks, compulsory licensing
